Helminth therapy and multiple sclerosis

International Journal for Parasitology

Volumn 43, Issue 3-4, 2013, Pages 259-274

  Fleming, J O ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Autoimmunity; Gut systemic CNS axis; Helminth therapy; Hygiene hypothesis; Immunoregulation; Multiple sclerosis; Necator; Trichuris

Indexed keywords

BETA INTERFERON; FINGOLIMOD; GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; MITOXANTRONE; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; PROTEOLIPID PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VITAMIN D;

ENDOPARASITE; HYGIENE; IMMUNITY; MEDICINE; NEMATODE; NEUROLOGY; SANITATION;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; B LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEVELOPING COUNTRY; DISEASE MODEL; ENVIRONMENTAL SANITATION; EPSTEIN BARR VIRUS; FASCIOLA HEPATICA; FOLLOW UP; GASTROINTESTINAL DISEASE; HELIGMOSOMOIDES POLYGYRUS; HUMAN; HYGIENE HYPOTHESIS; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOTHERAPY; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; NECATOR AMERICANUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SMOKING; STRONGYLOIDES VENEZUELENSIS; SUN EXPOSURE; T LYMPHOCYTE; TAENIA CRASSICEPS; TH1 CELL; TH17 CELL; TH2 CELL; THERAPY WITH HELMINTHS; TREATMENT OUTCOME; TRICHINELLA PSEUDOSPIRALIS; TRICHINELLA SPIRALIS; TRICHURIS SUIS; VITAMIN D DEFICIENCY;

ANIMALS; HELMINTHS; HUMANS; MULTIPLE SCLEROSIS; THERAPY WITH HELMINTHS;

ANIMALIA; NECATOR; TRICHURIS; VERMES;

EID: 84873730193     PISSN: 00207519     EISSN: 18790135     Source Type: Journal    
DOI: 10.1016/j.ijpara.2012.10.025     Document Type: Review

References (222)

1. Acs P., Kalman B. Pathogenesis of multiple sclerosis: what can we learn from the cuprizone model. Methods Mol. Biol. 2012, 900:403-431.
2. Adalid-Peralta L., Fragoso G., Fleury A., Sciutto E. Mechanisms underlying the induction of regulatory T cells and its relevance in the adaptive immune response in parasitic infections. Int. J. Biol. Sci. 2011, 7:1412-1426.
3. Aguirre-Cruz L., Flores-Rivera J., De La Cruz-Aguilera D.L., Rangel-Lopez E., Corona T. Multiple sclerosis in Caucasians and Latino Americans. Autoimmunity 2011, 44:571-575.
4. Ahlman H., Nilsson The gut as the largest endocrine organ in the body. Ann. Oncol. 2001, 12(Suppl. 2):S63-S68.
5. Anaya J.M. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun. Rev. 2012, 11:781-784.
6. Ascherio A., Munger K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007, 61:288-299.
7. Atlan H., Cohen I.R. Immune information, self-organization and meaning. Int. Immunol. 1998, 10:711-717.
8. Ayala F.J. "Nothing in biology makes sense except in the light of evolution": Theodosius Dobzhansky: 1900-1975. J. Hered. 1977, 68:3-10.
9. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 2002, 347:911-920.
10. Baecher-Allan C.M., Costantino C.M., Cvetanovich G.L., Ashley C.W., Beriou G., Dominguez-Villar M., Hafler D.A. CD2 costimulation reveals defective activity by human CD4+CD25(hi) regulatory cells in patients with multiple sclerosis. J. Immunol. 2011, 186:3317-3326.
11. Bager P., Kapel C., Roepstorff A., Thamsborg S., Arnved J., Ronborg S., Kristensen B., Poulsen L.K., Wohlfahrt J., Melbye M. Symptoms after ingestion of pig whipworm Trichuris suis eggs in a randomized placebo-controlled double-blind clinical trial. PLoS One 2011, 6:e22346.
12. Banks W.A., Erickson M.A. The blood-brain barrier and immune function and dysfunction. Neurobiol. Dis. 2010, 37:26-32.
13. Batoulis H., Recks M.S., Addicks K., Kuerten S. Experimental autoimmune encephalomyelitis - achievements and prospective advances. APMIS 2011, 119:819-830.
14. Behan P.O. Futility of the autoimmune orthodoxy in multiple sclerosis research. Expert Rev. Neurother. 2010, 10:1023-1025.
15. Behan P.O., Chaudhuri A. The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy. Inflammopharmacology 2010, 18:265-290.
16. Benson A., Pifer R., Behrendt C.L., Hooper L.V., Yarovinsky F. Gut commensal bacteria direct a protective immune response against Toxoplasma gondii. Cell Host Microbe 2009, 6:187-196.
17. Benzel F., Erdur H., Kohler S., Frentsch M., Thiel A., Harms L., Wandinger K.P., Rosche B. Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients. J. Helminthol. 2012, 86:339-347.
18. Berglund J. Alternative therapies: desperate measures. Nature 2012, 484. S11-S11.
19. Bernhardt H., Knoke M. Mycological aspects of gastrointestinal microflora. Scand. J. Gastroenterol. Suppl. 1997, 222:102-106.
20. Bilbo S.D., Wray G.A., Perkins S.E., Parker W. Reconstitution of the human biome as the most reasonable solution for epidemics of allergic and autoimmune diseases. Med. Hypotheses 2011, 77:494-504.
21. Blount D., Hooi D., Feary J., Venn A., Telford G., Brown A., Britton J., Pritchard D. Immunologic profiles of persons recruited for a randomized, placebo-controlled clinical trial of hookworm infection. Am. J. Trop. Med. Hyg. 2009, 81:911-916.
22. Bluestone J.A. Mechanisms of tolerance. Immunol. Rev. 2011, 241:5-19.
23. Boppana S., Huang H., Ito K., Dhib-Jalbut S. Immunologic aspects of multiple sclerosis. Mt Sinai J. Med. 2011, 78:207-220.
24. Broadhurst M.J., Leung J.M., Kashyap V., McCune J.M., Mahadevan U., McKerrow J.H., Loke P. IL-22+CD4+ T cells are associated with therapeutic Trichuris trichiura infection in an ulcerative colitis patient. Sci. Transl. Med. 2010, 2:60ra88.
25. Brooker S., Bethony J., Hotez P.J. Human hookworm infection in the 21st century. Adv. Parasitol. 2004, 58:197-288.
26. Buchter B., Dunkel M., Li J. Multiple sclerosis: a disease of affluence?. Neuroepidemiology 2012, 39:51-56.
27. Cabre P. Migration and multiple sclerosis: the French West Indies experience. J. Neurol. Sci. 2007, 262:117-121.
28. Cabre P. Environmental changes and epidemiology of multiple sclerosis in the French West Indies. J. Neurol. Sci. 2009, 286:58-61.
29. Cabre P., Signate A., Olindo S., Merle H., Caparros-Lefebvre D., Bera O., Smadja D. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 2005, 128:2899-2910.
30. Cantacessi C., Young N.D., Nejsum P., Jex A.R., Campbell B.E., Hall R.S., Thamsborg S.M., Scheerlinck J.P., Gasser R.B. The transcriptome of Trichuris suis - first molecular insights into a parasite with curative properties for key immune diseases of humans. PLoS One 2011, 6:e23590.
31. Carbajal K.S., Weinger J.G., Whitman L.M., Schaumburg C.S., Lane T.E. Surgical transplantation of mouse neural stem cells into the spinal cords of mice infected with neurotropic mouse hepatitis virus. J. Vis. Exp. 2011, e2834.
32. Chandrasoma P., Taylor C.R. Concise Pathology, McGraw-Hill's AccessMedicine. Lange Educational Library 1998, McGraw-Hill, New York. third ed.
33. Chaudhuri A., Behan P.O. Multiple sclerosis: looking beyond autoimmunity. J. R. Soc. Med. 2005, 98:303-306.
34. Chiuso-Minicucci F., Van D.B., Zorzella-Pezavento S.F., Peres R.S., Ishikawa L.L., Rosa L.C., Franca T.G., Turato W.M., Amarante A.F., Sartori A. Experimental autoimmune encephalomyelitis evolution was not modified by multiple infections with Strongyloides venezuelensis. Parasite Immunol. 2011, 33:303-308.
35. Chow S.C., Brown A., Pritchard D. The human hookworm pathogen Necator americanus induces apoptosis in T lymphocytes. Parasite Immunol. 2000, 22:21-29.
36. Clancy R. Immunobiotics and the probiotic evolution. FEMS Immunol. Med. Microbiol. 2003, 38:9-12.
37. Cohen I.R., Harel D. Explaining a complex living system: dynamics, multi-scaling and emergence. J. R. Soc. Interface 2007, 4:175-182.
38. Collins S.M., Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009, 136:2003-2014.
39. Cooke A. Infection and autoimmunity. Blood Cells Mol. Dis. 2009, 42:105-107.
40. Cooke A. Parasitic worms and inflammatory disease. Curr. Opin. Rheumatol. 2012, 24:394-400.
41. Correale J., Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann. Neurol. 2007, 61:97-108.
42. Correale J., Farez M. Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms. J. Immunol. 2009, 183:5999-6012.
43. Correale J., Farez M.F. The impact of parasite infections on the course of multiple sclerosis. J. Neuroimmunol. 2011, 233:6-11.
44. Correale J., Farez M.F. Does helminth activation of toll-like receptors modulate immune response in multiple sclerosis patients?. Front. Cell. Infect. Microbiol. 2012, 2:112.
45. Correale J., Farez M., Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann. Neurol. 2008, 64:187-199.
46. Corthals A.P. Multiple sclerosis is not a disease of the immune system. Q. Rev. Biol. 2011, 86:287-321.
47. Danilowicz-Luebert E., O'Regan N.L., Steinfelder S., Hartmann S. Modulation of specific and allergy-related immune responses by helminths. J. Biomed. Biotechnol. 2011, 2011:821578.
48. Das U.N. Is multiple sclerosis a proresolution deficiency disorder?. Nutrition 2012, 28:951-958.
49. Datta S., Sajja B.R., He R., Gupta R.K., Wolinsky J.S., Narayana P.A. Segmentation of gadolinium-enhanced lesions on MRI in multiple sclerosis. J. Magn. Reson. Imaging 2007, 25:932-937.
50. Daumer M., Neuhaus A., Morrissey S., Hintzen R., Ebers G.C. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009, 72:705-711.
51. de Lorenzo V., Galperin M. Microbial systems biology: bottom up and top down. FEMS Microbiol. Rev. 2009, 33:1-2.
52. Denic A., Johnson A.J., Bieber A.J., Warrington A.E., Rodriguez M., Pirko I. The relevance of animal models in multiple sclerosis research. Pathophysiology. 2011, 18:21-29.
53. d'Hennezel E., Bin Dhuban K., Torgerson T., Piccirillo C. The immunogenetics of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 2012, 49:291-302.
54. Dockray G.J. Luminal sensing in the gut: an overview. J. Physiol. Pharmacol. 2003, 54(Suppl. 4):9-17.
55. Dong Y., Manfredini F., Dimopoulos G. Implication of the mosquito midgut microbiota in the defense against malaria parasites. PLoS Pathog. 2009, 5:e1000423.
56. Eberl G. A new vision of immunity: homeostasis of the superorganism. Mucosal Immunol. 2010, 3:450-460.
57. Edwards L.J., Constantinescu C.S. Parasite immunomodulation in autoimmune disease: focus on multiple sclerosis. Expert Rev. Clin. Immunol. 2009, 5:487-489.
58. Edwards L.J., Robins R.A., Constantinescu C.S. Th17/Th1 phenotype in demyelinating disease. Cytokine 2010, 50:19-23.
59. Edwards L.J., Sharrack B., Ismail A., Tumani H., Constantinescu C.S. Central inflammation versus peripheral regulation in multiple sclerosis. J. Neurol. 2011, 258:1518-1527.
60. Elliott D.E., Weinstock J.V. Helminth-host immunological interactions: prevention and control of immune-mediated diseases. Ann. N. Y. Acad. Sci. 2012, 1247:83-96.
61. El-Malky M., Nabih N., Heder M., Saudy N., El-Mahdy M. Helminth infections: therapeutic potential in autoimmune disorders. Parasite Immunol. 2011, 33:589-593.
62. Erb K.J. Can helminths or helminth-derived products be used in humans to prevent or treat allergic diseases?. Trends Immunol. 2009, 30:75-82.
63. Esplugues E., Huber S., Gagliani N., Hauser A.E., Town T., Wan Y.Y., O'Connor W., Rongvaux A., Van Rooijen N., Haberman A.M., Iwakura Y., Kuchroo V.K., Kolls J.K., Bluestone J.A., Herold K.C., Flavell R.A. Control of TH17 cells occurs in the small intestine. Nature 2011, 475:514-518.
64. Etemadifar M., Maghzi A.H. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult. Scler. 2011, 17:1022-1027.
65. Feary J., Venn A., Brown A., Hooi D., Falcone F.H., Mortimer K., Pritchard D.I., Britton J. Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study. Clin. Exp. Allergy 2009, 39:1060-1068.
66. Feary J.R., Venn A.J., Mortimer K., Brown A.P., Hooi D., Falcone F.H., Pritchard D.I., Britton J.R. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin. Exp. Allergy 2010, 40:299-306.
67. Ferraro M.F., Moreno A.S., Castelli E.C., Donadi E.A., Palma M.S., Arcuri H.A., Lange A.P., Bork K., Sarti W., Arruda L.K. A single nucleotide deletion at the C1 inhibitor gene as the cause of hereditary angioedema: insights from a Brazilian family. Allergy 2011, 66:1384-1390.
68. Fischetti V.A., Nelson D., Schuch R. Reinventing phage therapy: are the parts greater than the sum?. Nat. Biotechnol. 2006, 24:1508-1511.
69. Fleming J.O. Helminths and multiple sclerosis: will old friends give us new treatments for MS?. J. Neuroimmunol. 2011, 233:3-5.
70. Fleming J.O., Cook T.D. Multiple sclerosis and the hygiene hypothesis. Neurology 2006, 67:2085-2086.
71. Fleming J.O., Isaak A., Lee J.E., Luzzio C.C., Carrithers M.D., Cook T.D., Field A.S., Boland J., Fabry Z. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult. Scler. 2011, 17:743-754.
72. Fleshner M. The gut microbiota: a new player in the innate immune stress response?. Brain Behav. Immun. 2011, 25:395-396.
73. Fletcher J.M., Lonergan R., Costelloe L., Kinsella K., Moran B., O'Farrelly C., Tubridy N., Mills K.H. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 2009, 183:7602-7610.
74. Florin T.H., Zhu G., Kirk K.M., Martin N.G. Shared and unique environmental factors determine the ecology of methanogens in humans and rats. Am. J. Gastroenterol. 2000, 95:2872-2879.
75. Forsythe P., Kunze W.A. Voices from with. Cell. Mol. Life Sci. 2012, 70:55-69.
76. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942-955.
77. Fumagalli M., Pozzoli U., Cagliani R., Comi G.P., Riva S., Clerici M., Bresolin N., Sironi M. Parasites represent a major selective force for interleukin genes and shape the genetic predisposition to autoimmune conditions. J. Exp. Med. 2009, 206:1395-1408.
78. Fumagalli M., Pozzoli U., Cagliani R., Comi G.P., Bresolin N., Clerici M., Sironi M. The landscape of human genes involved in the immune response to parasitic worms. BMC Evol. Biol. 2010, 10:264.
79. Gale E.A. A missing link in the hygiene hypothesis?. Diabetologia 2002, 45:588-594.
80. Gandhi K.S., McKay F.C., Cox M., Riveros C., Armstrong N., Heard R.N., Vucic S., Williams D.W., Stankovich J., Brown M., Danoy P., Stewart G.J., Broadley S., Moscato P., Lechner-Scott J., Scott R.J., Booth D.R. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum. Mol. Genet. 2010, 19:2134-2143.
81. Garcia E.S., Castro D.P., Figueiredo M.B., Azambuja P. Immune homeostasis to microorganisms in the guts of triatomines (Reduviidae) - a review. Mem. Inst. Oswaldo Cruz 2010, 105:605-610.
82. Gershon M.D., Ratcliffe E.M. Developmental biology of the enteric nervous system: pathogenesis of Hirschsprung's disease and other congenital dysmotilities. Semin. Pediatr. Surg. 2004, 13:224-235.
83. Goldenberg M.M. Multiple sclerosis review. Pharm. Ther. 2012, 37:175-184.
84. Gonsette R.E. Self-tolerance in multiple sclerosis. Acta Neurol. Belg. 2012, 112:133-140.
85. Gourraud P.A., Harbo H.F., Hauser S.L., Baranzini S.E. The genetics of multiple sclerosis: an up-to-date review. Immunol. Rev. 2012, 248:87-103.
86. Graham S.P., Trees A.J., Collins R.A., Moore D.M., Guy F.M., Taylor M.J., Bianco A.E. Down-regulated lymphoproliferation coincides with parasite maturation and with the collapse of both gamma interferon and interleukin-4 responses in a bovine model of onchocerciasis. Infect. Immun. 2001, 69:4313-4319.
87. Gruden-Movsesijan A., Ilic N., Mostarica-Stojkovic M., Stosic-Grujicic S., Milic M., Sofronic-Milosavljevic L. Mechanisms of modulation of experimental autoimmune encephalomyelitis by chronic Trichinella spiralis infection in Dark Agouti rats. Parasite Immunol. 2010, 32:450-459.
88. Handel A.E., Lincoln M.R., Ramagopalan S.V. Of mice and men: experimental autoimmune encephalitis and multiple sclerosis. Eur. J. Clin. Invest. 2011, 41:1254-1258.
89. Harnett W., Harnett M.M. Molecular basis of worm-induced immunomodulation. Parasite Immunol. 2006, 28:535-543.
90. Hasseldam, H., Hansen, C.S., Johansen, F.F., 2012. Immunomodulatory effects of helminths and protozoa in multiple sclerosis and experimental autoimmune encephalomyelitis. Parasite Immunol, http://dx.doi.org/10.111/pim.12023. [Epub ahead of print].
91. Hayes K.S., Bancroft A.J., Goldrick M., Portsmouth C., Roberts I.S., Grencis R.K. Exploitation of the intestinal microflora by the parasitic nematode Trichuris muris. Science 2010, 328:1391-1394.
92. Hoerauf A. Microflora, helminths, and the immune system - who controls whom?. N. Engl. J. Med. 2010, 363:1476-1478.
93. Hohlfeld R., Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. USA 2004, 101(Suppl. 2):14599-14606.
94. Honda K., Littman D.R. The microbiome in infectious disease and inflammation. Annu. Rev. Immunol. 2012, 30:759-795.
95. Hsu S.J., Tseng P.H., Chen P.J. Trichuris suis therapy for ulcerative colitis: nonresponsive patients may need anti-helminth therapy. Gastroenterology 2005, 129:768-769. author reply 769.
96. Inshasi J., Thakre M. Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int. J. Neurosci. 2011, 121:393-398.
97. Jha S., Srivastava S.Y., Brickey W.J., Iocca H., Toews A., Morrison J.P., Chen V.S., Gris D., Matsushima G.K., Ting J.P. The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J. Neurosci. 2010, 30:15811-15820.
98. Johnston M.J., MacDonald J.A., McKay D.M. Parasitic helminths: a pharmacopeia of anti-inflammatory molecules. Parasitology 2009, 136:125-147.
99. Joller N., Peters A., Anderson A.C., Kuchroo V.K. Immune checkpoints in central nervous system autoimmunity. Immunol. Rev. 2012, 248:122-139.
100. Jouvin M.H., Kinet J.P. Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis. J. Allergy Clin. Immunol. 2012, 130:3-10. quiz 11-12.
101. Kelly D., Mulder I.E. Microbiome and immunological interactions. Nutr. Rev. 2012, 70(Suppl. 1):S18-S30.
102. Kipp M., van der Valk P., Amor S. Pathology of multiple sclerosis. CNS Neurol. Disord.: Drug Targets 2012, 11:506-517.
103. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity - friends or foes?. Trends Immunol. 2009, 30:409-414.
104. Koch-Henriksen N., Sorensen P.S. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010, 9:520-532.
105. Koch-Henriksen N., Sorensen P.S. Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?. J. Neurol. Sci. 2011, 311:58-63.
106. Kradin R.L., Badizadegan K., Auluck P., Korzenik J., Lauwers G.Y. Iatrogenic Trichuris suis infection in a patient with Crohn disease. Arch. Pathol. Lab. Med. 2006, 130:718-720.
107. Krone B., Grange J.M. Paradigms in multiple sclerosis: time for a change, time for a unifying concept. Inflammopharmacology 2011, 19:187-195.
108. Kuerten S., Angelov D.N. Comparing the CNS morphology and immunobiology of different EAE models in C57BL/6 mice - a step towards understanding the complexity of multiple sclerosis. Ann. Anat. 2008, 190:1-15.
109. Kuerten S., Lehmann P.V. The immune pathogenesis of experimental autoimmune encephalomyelitis: lessons learned for multiple sclerosis?. J. Interferon Cytokine Res. 2011, 31:907-916.
110. Kuijk L.M., Klaver E.J., Kooij G., van der Pol S.M., Heijnen P., Bruijns S.C., Kringel H., Pinelli E., Kraal G., de Vries H.E., Dijkstra C.D., Bouma G., van Die I. Soluble helminth products suppress clinical signs in murine experimental autoimmune encephalomyelitis and differentially modulate human dendritic cell activation. Mol. Immunol. 2012, 51:210-218.
111. La Flamme A.C., Ruddenklau K., Backstrom B.T. Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infect. Immun. 2003, 71:4996-5004.
112. Lammie P.J., Katz S.P. Immunoregulation in experimental filariasis. II. Responses to parasite and nonparasite antigens in jirds with Brugia pahangi. J. Immunol. 1983, 130:1386-1389.
113. Lampa J., Westman M., Kadetoff D., Agreus A.N., Le Maitre E., Gillis-Haegerstrand C., Andersson M., Khademi M., Corr M., Christianson C.A., Delaney A., Yaksh T.L., Kosek E., Svensson C.I. Peripheral inflammatory disease associated with centrally activated IL-1 system in humans and mice. Proc. Natl. Acad. Sci. USA 2012, 109:12728-12733.
114. Lee Y.K., Mazmanian S.K. Has the microbiota played a critical role in the evolution of the adaptive immune system?. Science 2010, 330:1768-1773.
115. Lee Y.K., Menezes J.S., Umesaki Y., Mazmanian S.K. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2011, 108(Suppl. 1):4615-4622.
116. Leibowitz U., Antonovsky A., Medalie J.M., Smith H.A., Halpern L., Alter M. Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J. Neurol. Neurosurg. Psychiatry 1966, 29:60-68.
117. Li D.K., Li M.J., Traboulsee A., Zhao G., Riddehough A., Paty D. The use of MRI as an outcome measure in clinical trials. Adv. Neurol. 2006, 98:203-226.
118. Liu B., Shen Y., Xiao K., Tang Y., Cen L., Wei J. Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurol. Res. 2012, 34:163-171.
119. Lowther D.E., Hafler D.A. Regulatory T cells in the central nervous system. Immunol. Rev. 2012, 248:156-169.
120. Lundmark F., Duvefelt K., Iacobaeus E., Kockum I., Wallstrom E., Khademi M., Oturai A., Ryder L.P., Saarela J., Harbo H.F., Celius E.G., Salter H., Olsson T., Hillert J. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 2007, 39:1108-1113.
121. Mackay I.R. Science, medicine, and the future: tolerance and autoimmunity. BMJ 2000, 321:93-96.
122. Maizels R.M., Balic A., Gomez-Escobar N., Nair M., Taylor M.D., Allen J.E. Helminth parasites - masters of regulation. Immunol. Rev. 2004, 201:89-116.
123. Markowitz C.E. Interferon-beta: mechanism of action and dosing issues. Neurology 2007, 68:S8-S11.
124. Martin F.P., Dumas M.E., Wang Y., Legido-Quigley C., Yap I.K., Tang H., Zirah S., Murphy G.M., Cloarec O., Lindon J.C., Sprenger N., Fay L.B., Kochhar S., van Bladeren P., Holmes E., Nicholson J.K. A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol. Syst. Biol. 2007, 3:112.
125. Mayer E.A. Gut feelings: the emerging biology of gut-brain communication. Nat. Rev. Neurosci. 2011, 12:453-466.
126. Maynard C.L., Weaver C.T. Intestinal effector T cells in health and disease. Immunity 2009, 31:389-400.
127. McCarthy D.P., Richards M.H., Miller S.D. Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler's virus-induced demyelinating disease. Methods Mol. Biol. 2012, 900:381-401.
128. McFarland H.F., Barkhof F., Antel J., Miller D.H. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult. Scler. 2002, 8:40-51.
129. McKay D.M. The beneficial helminth parasite?. Parasitology 2006, 132:1-12.
130. McLeod J.G., Hammond S.R., Kurtzke J.F. Migration and multiple sclerosis in United Kingdom and Ireland immigrants to Australia: a reassessment. II. Characteristics of early (pre-1947) compared to later migrants. J. Neurol. 2012, 259:684-693.
131. Medzhitov R., Schneider D.S., Soares M.P. Disease tolerance as a defense strategy. Science 2012, 335:936-941.
132. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
133. Miller D.H., Albert P.S., Barkhof F., Francis G., Frank J.A., Hodgkinson S., Lublin F.D., Paty D.W., Reingold S.C., Simon J. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann. Neurol. 1996, 39:6-16.
134. Mix E., Meyer-Rienecker H., Hartung H.P., Zettl U.K. Animal models of multiple sclerosis - potentials and limitations. Prog. Neurobiol. 2010, 92:386-404.
135. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., Richert J.R., Siegel J.N. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001, 44:2862-2869.
136. Moreno B., Jukes J.P., Vergara-Irigaray N., Errea O., Villoslada P., Perry V.H., Newman T.A. Systemic inflammation induces axon injury during brain inflammation. Ann. Neurol. 2011, 70:932-942.
137. Mortimer K., Brown A., Feary J., Jagger C., Lewis S., Antoniak M., Pritchard D., Britton J. Dose-ranging study for trials of therapeutic infection with Necator americanus in humans. Am. J. Trop. Med. Hyg. 2006, 75:914-920.
138. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
139. Mowat A.M., Viney J.L. The anatomical basis of intestinal immunity. Immunol. Rev. 1997, 156:145-166.
140. Murta, V., Ferrari, C.C., 2012. Influence of Peripheral inflammation on the progression of multiple sclerosis: evidence from the clinic and experimental animal models. Mol. Cell. Neurosci, [Epub ahead of print]. http://dx.doi.org/10.1016/j.mcn.2012.06.004.
141. Nicholson G., Rantalainen M., Maher A.D., Li J.V., Malmodin D., Ahmadi K.R., Faber J.H., Hallgrimsdottir I.B., Barrett A., Toft H., Krestyaninova M., Viksna J., Neogi S.G., Dumas M.E., Sarkans U., The Molpage C., Silverman B.W., Donnelly P., Nicholson J.K., Allen M., Zondervan K.T., Lindon J.C., Spector T.D., McCarthy M.I., Holmes E., Baunsgaard D., Holmes C.C. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol. Syst. Biol. 2011, 7:525.
142. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
143. Noble D. Claude Bernard, the first systems biologist, and the future of physiology. Exp. Physiol. 2008, 93:16-26.
144. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
145. Noverr M.C., Huffnagle G.B. Does the microbiota regulate immune responses outside the gut?. Trends Microbiol. 2004, 12:562-568.
146. Nylander A., Hafler D.A. Multiple sclerosis. J. Clin. Invest. 2012, 122:1180-1188.
147. Ochoa-Reparaz J., Mielcarz D.W., Wang Y., Begum-Haque S., Dasgupta S., Kasper D.L., Kasper L.H. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010, 3:487-495.
148. Okada H., Kuhn C., Feillet H., Bach J.F. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin. Exp. Immunol. 2010, 160:1-9.
149. Orton S.M., Ramagopalan S.V., Brocklebank D., Herrera B.M., Dyment D.A., Yee I.M., Sadovnick A.D., Ebers G.C. Effect of immigration on multiple sclerosis sex ratio in Canada: the Canadian Collaborative Study. J. Neurol. Neurosurg. Psychiatry 2010, 81:31-36.
150. Pabst O., Mowat A.M. Oral tolerance to food protein. Mucosal Immunol. 2012, 5:232-239.
151. Pabst R., Russell M.W., Brandtzaeg P. Tissue distribution of lymphocytes and plasma cells and the role of the gut. Trends Immunol. 2008, 29:206-208.
152. Parra G.I., Bergmann C.C., Phares T.W., Hinton D.R., Atkinson R., Stohlman S.A. Gamma interferon signaling in oligodendrocytes is critical for protection from neurotropic coronavirus infection. J. Virol. 2010, 84:3111-3115.
153. Phillips R.J., Powley T.L. Macrophages associated with the intrinsic and extrinsic autonomic innervation of the rat gastrointestinal tract. Auton. Neurosci. 2012, 169:12-27.
154. Pollard T.M. Western Diseases: An Evolutionary Perspective 2008, Cambridge University Press, Cambridge, New York.
155. Popescu B.F., Lucchinetti C.F. Pathology of demyelinating diseases. Annu. Rev. Pathol. 2012, 7:185-217.
156. Pritchard D.I., Blount D.G., Schmid-Grendelmeier P., Till S.J. Parasitic worm therapy for allergy: is this incongruous or avant-garde medicine?. Clin. Exp. Allergy 2012, 42:505-512.
157. Radford-Smith G.L. Will worms really cure Crohn's disease?. Gut 2005, 54:6-8.
158. Ransohoff R.M. EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol. 2006, 27:167-168.
159. Ransohoff R.M., Cardona A.E. The myeloid cells of the central nervous system parenchyma. Nature 2010, 468:253-262.
160. Raybould H.E. Gut chemosensing: interactions between gut endocrine cells and visceral afferents. Auton. Neurosci. 2010, 153:41-46.
161. Reddy A., Fried B. An update on the use of helminths to treat Crohn's and other autoimmune diseases. Parasitol. Res. 2009, 104:217-221.
162. Reyes A., Haynes M., Hanson N., Angly F.E., Heath A.C., Rohwer F., Gordon J.I. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 2010, 466:334-338.
163. Reyes J.L., Espinoza-Jimenez A.F., Gonzalez M.I., Verdin L., Terrazas L.I. Taenia crassiceps infection abrogates experimental autoimmune encephalomyelitis. Cell. Immunol. 2011, 267:77-87.
164. Reyes A., Semenkovich N.P., Whiteson K., Rohwer F., Gordon J.I. Going viral: next-generation sequencing applied to phage populations in the human gut. Nat. Rev. Microbiol. 2012, 10:607-617.
165. Rhee S.H., Pothoulakis C., Mayer E.A. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat. Rev. Gastroenterol. Hepatol. 2009, 6:306-314.
166. Rice J. Animal models: not close enough. Nature 2012, 484:S9.
167. Roep B.O., Buckner J., Sawcer S., Toes R., Zipp F. The problems and promises of research into human immunology and autoimmune disease. Nat. Med. 2012, 18:48-53.
168. Ron-Harel N., Cardon M., Schwartz M. Brain homeostasis is maintained by "danger" signals stimulating a supportive immune response within the brain's borders. Brain Behav. Immun. 2011, 25:1036-1043.
169. Rook G.A. Hygiene hypothesis and autoimmune diseases. Clin. Rev. Allergy Immunol. 2012, 42:5-15.
170. Rook G.A., Adams V., Hunt J., Palmer R., Martinelli R., Brunet L.R. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin. Immunopathol. 2004, 25:237-255.
171. Sajedi S.A., Abdollahi F. Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries. BMC Neurol. 2012, 12:100.
172. Sawcer S. The major cause of multiple sclerosis is environmental: genetics has a minor role - no. Mult. Scler. 2011, 17:1174-1175.
173. Selmi C., Mix E., Zettl U.K. A clear look at the neuroimmunology of multiple sclerosis and beyond. Autoimmun. Rev. 2012, 11:159-162.
174. Sener A.G., Afsar I. Infection and autoimmune disease. Rheumatol. Int. 2012, 32:3331-3338.
175. Sewell D., Qing Z., Reinke E., Elliot D., Weinstock J., Sandor M., Fabry Z. Immunomodulation of experimental autoimmune encephalomyelitis by helminth ova immunization. Int. Immunol. 2003, 15:59-69.
176. Smith K.M., Guerau-de-Arellano M., Costinean S., Williams J.L., Bottoni A., Mavrikis Cox G., Satoskar A.R., Croce C.M., Racke M.K., Lovett-Racke A.E., Whitacre C.C. MiR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J. Immunol. 2012, 189:1567-1576.
177. Smits H.H., Everts B., Hartgers F.C., Yazdanbakhsh M. Chronic helminth infections protect against allergic diseases by active regulatory processes. Curr. Allergy Asthma Rep. 2010, 10:3-12.
178. Sormani M.P., Miller D.H., Comi G., Barkhof F., Rovaris M., Bruzzi P., Filippi M. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J. Neurol. Neurosurg. Psychiatry 2001, 70:494-499.
179. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
180. Srinivasan N. Telling apart friend from foe: discriminating between commensals and pathogens at mucosal sites. Innate Immun. 2010, 16:391-404.
181. Sriram S. Role of glial cells in innate immunity and their role in CNS demyelination. J. Neuroimmunol. 2011, 239:13-20.
182. Sriram S., Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 2005, 58:939-945.
183. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
184. Stoll N.R. This wormy world. J. Parasitol. 1947, 33:1-18.
185. Stys P.K., Zamponi G.W., van Minnen J., Geurts J.J. Will the real multiple sclerosis please stand up?. Nat. Rev. Neurosci. 2012, 13:507-514.
186. Summers R.W., Elliott D.E., Qadir K., Urban J.F., Thompson R., Weinstock J.V. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am. J. Gastroenterol. 2003, 98:2034-2041.
187. Summers R.W., Elliott D.E., Urban J.F., Thompson R., Weinstock J.V. Trichuris suis therapy in Crohn's disease. Gut 2005, 54:87-90.
188. Summers R.W., Elliott D.E., Urban J.F., Thompson R.A., Weinstock J.V. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005, 128:825-832.
189. Summers R.W., Elliott D.E., Weinstock J.V. Therapeutic colonization with Trichuris suis. Arch. Pathol. Lab. Med. 2006, 130:1753. author reply 1753-1754.
190. t Hart B.A., Gran B., Weissert R. EAE: imperfect but useful models of multiple sclerosis. Trends Mol. Med. 2011, 17:119-125.
191. Taylor B.V. The major cause of multiple sclerosis is environmental: genetics has a minor role - yes. Mult. Scler. 2011, 17:1171-1173.
192. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis GroupThe University of British Columbia MS/MRI Analysis Group.
193. Tracey K.J. Understanding immunity requires more than immunology. Nat. Immunol. 2010, 11:561-564.
194. Trandem K., Anghelina D., Zhao J., Perlman S. Regulatory T cells inhibit T cell proliferation and decrease demyelination in mice chronically infected with a coronavirus. J. Immunol. 2010, 184:4391-4400.
195. Travers M.A., Florent I., Kohl L., Grellier P. Probiotics for the control of parasites: an overview. J. Parasitol. Res. 2011, 2011:610769.
196. Tundup S., Srivastava L., Harn D.A. Polarization of host immune responses by helminth-expressed glycans. Ann. N. Y. Acad. Sci. 2012, 1253:E1-E13.
197. Tveita A.A. The danger model in deciphering autoimmunity. Rheumatology (Oxford) 2010, 49:632-639.
198. van Horssen J., Singh S., van der Pol S., Kipp M., Lim J.L., Peferoen L., Gerritsen W., Kooi E.J., Witte M.E., Geurts J.J., de Vries H.E., Peferoen-Baert R., van den Elsen P.J., van der Valk P., Amor S. Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation. J. Neuroinflammation 2012, 9:156.
199. Van Kruiningen H.J., West A.B. Iatrogenic Trichuris suis infection. Arch. Pathol. Lab. Med. 2007, 131:180.
200. van Noort J.M., van den Elsen P.J., van Horssen J., Geurts J.J., van der Valk P., Amor S. Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies. CNS Neurol. Disord.: Drug Targets 2011, 10:68-81.
201. van Rensburg S.J., Kotze M.J., van Toorn R. The conundrum of iron in multiple sclerosis - time for an individualised approach. Metab. Brain Dis. 2012, 27:239-253.
202. Walk S.T., Blum A.M., Ewing S.A., Weinstock J.V., Young V.B. Alteration of the murine gut microbiota during infection with the parasitic helminth Heligmosomoides polygyrus. Inflamm. Bowel Dis. 2010, 16:1841-1849.
203. Walsh K.P., Brady M.T., Finlay C.M., Boon L., Mills K.H. Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J. Immunol. 2009, 183:1577-1586.
204. Wang X., Wang B.R., Zhang X.J., Xu Z., Ding Y.Q., Ju G. Evidences for vagus nerve in maintenance of immune balance and transmission of immune information from gut to brain in STM-infected rats. World J. Gastroenterol. 2002, 8:540-545.
205. Weiner H.L., da Cunha A.P., Quintana F., Wu H. Oral tolerance. Immunol. Rev. 2011, 241:241-259.
206. Weinstock J.V. Autoimmunity: the worm returns. Nature 2012, 491:183-185.
207. Weinstock J.V., Summers R.W., Elliott D.E., Qadir K., Urban J.F., Thompson R. The possible link between de-worming and the emergence of immunological disease. J. Lab. Clin. Med. 2002, 139:334-338.
208. Wiendl H., Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002, 16:183-200.
209. Wilson I. Top-down versus bottom-up-rediscovering physiology via systems biology?. Mol. Syst. Biol. 2007, 3:113.
210. Wilson M.S., Taylor M.D., O'Gorman M.T., Balic A., Barr T.A., Filbey K., Anderton S.M., Maizels R.M. Helminth-induced CD19+CD23hi B cells modulate experimental allergic and autoimmune inflammation. Eur. J. Immunol. 2010, 40:1682-1696.
211. Wolff M.J., Broadhurst M.J., Loke P. Helminthic therapy: improving mucosal barrier function. Trends Parasitol. 2012, 28:187-194.
212. Wolfgram F. What if multiple sclerosis isn't an immunological or a viral disease? The case for a circulating toxin. Neurochem. Res. 1979, 4:1-14.
213. Wootla B., Eriguchi M., Rodriguez M. Is multiple sclerosis an autoimmune disease?. Autoimmune Dis. 2012, 2012:969657.
214. Wu Z., Nagano I., Asano K., Takahashi Y. Infection of non-encapsulated species of Trichinella ameliorates experimental autoimmune encephalomyelitis involving suppression of Th17 and Th1 response. Parasitol. Res. 2010, 107:1173-1188.
215. Wu S., Li R.W., Li W., Beshah E., Dawson H.D., Urban J.F. Worm burden-dependent disruption of the porcine colon microbiota by Trichuris suis infection. PLoS One 2012, 7:e35470.
216. Zamboni P., Galeotti R., Menegatti E., Malagoni A.M., Tacconi G., Dall'Ara S., Bartolomei I., Salvi F. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2009, 80:392-399.
217. Zaph C., Troy A.E., Taylor B.C., Berman-Booty L.D., Guild K.J., Du Y., Yost E.A., Gruber A.D., May M.J., Greten F.R., Eckmann L., Karin M., Artis D. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature 2007, 446:552-556.
218. Zheng X., Hu X., Zhou G., Lu Z., Qiu W., Bao J., Dai Y. Soluble egg antigen from Schistosoma japonicum modulates the progression of chronic progressive experimental autoimmune encephalomyelitis via Th2-shift response. J. Neuroimmunol. 2008, 194:107-114.
219. Zhu B., Trikudanathan S., Zozulya A.L., Sandoval-Garcia C., Kennedy J.K., Atochina O., Norberg T., Castagner B., Seeberger P., Fabry Z., Harn D., Khoury S.J., Guleria I. Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis. Clin. Immunol. 2012, 142:351-361.
220. Ziemssen T. What can we learn from failed clinical trials in multiple sclerosis?. J. Neurol. 2008, 255(Suppl. 6):97-101.
221. Zozulya A.L., Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat. Clin. Pract. Neurol. 2008, 4:384-398.
222. Zozulya A.L., Clarkson B.D., Ortler S., Fabry Z., Wiendl H. The role of dendritic cells in CNS autoimmunity. J. Mol. Med. (Berl.) 2010, 88:535-544.